Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Frederick Wood

Cardiovascular Disease Murrieta, CA Medical Doctor

NPI 1164479473 CMS profile 279388

25470 Medical Center Dr Ste 105, Murrieta, CA 92562

Open in the dashboard

General payments

$18,289

1,010 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Frederick Wood of Murrieta, CA is reported in the CMS Open Payments database as having received $18,289 across 1,010 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,382 105
2024 General $2,500 121
2023 General $2,689 139
2022 General $2,560 147
2021 General $3,042 173
2020 General $2,684 153
2019 General $2,432 172

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frederick Wood
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Frederick Wood were reported at $2,382. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Frederick Wood Cardiovascular Disease median Middle half National median
2019 $2,432 $450 $127–$1,392 $163
2020 $2,684 $242 $77–$751 $114
2021 $3,042 $335 $101–$1,037 $132
2022 $2,560 $395 $121–$1,211 $149
2023 $2,689 $443 $136–$1,283 $160
2024 $2,500 $450 $136–$1,323 $164
2025 $2,382 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,377 166 payments
  2. AstraZeneca Pharmaceuticals LP $1,784 87 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,630 69 payments
  4. Janssen Pharmaceuticals, Inc $1,622 101 payments
  5. Pfizer Inc. $1,510 91 payments
  6. Amarin Pharma Inc. $1,394 86 payments
  7. E.R. Squibb & Sons, L.L.C. $1,158 62 payments
  8. Sanofi-Aventis U.S. LLC $1,099 55 payments
  9. Amgen Inc. $724 36 payments
  10. Esperion Therapeutics, Inc. $597 44 payments
  11. Other $4,394 213 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,146 1,002 payments
  2. Education $143 8 payments
Products named General payments · program years 2019–2025
  1. XARELTO $1,622 101 payments
  2. FARXIGA $1,398 69 payments
  3. ELIQUIS Cardiovascular;Metabolic Disease $1,354 82 payments
  4. ENTRESTO $1,313 93 payments
  5. Vascepa $1,042 64 payments
  6. JARDIANCE Diabetes $966 43 payments
  7. ELIQUIS Cardiovascular $899 50 payments
  8. LEQVIO $671 41 payments
  9. VERQUVO $671 35 payments
  10. JARDIANCE Diabetes $664 26 payments
  11. Other $9,320 525 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

1,701

Median for Cardiology: 2,533

Drug cost

$578,041

Median for Cardiology: $485,213

Branded share of claims

32.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 130 $154,306
Xarelto Rivaroxaban Brand 65 $75,433
Jardiance Empagliflozin Brand 38 $50,944
Entresto Sacubitril/Valsartan Brand 30 $48,274
Vascepa Icosapent Ethyl Brand 47 $43,040
Farxiga Dapagliflozin Propanediol Brand 22 $31,485
Repatha Sureclick Evolocumab Brand 18 $28,631
Ozempic Semaglutide Brand 17 $25,271
Brilinta Ticagrelor Brand 19 $22,094
Multaq Dronedarone Hcl Brand 12 $18,036

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$290,106

Of which drugs: $1,044

Medicare patients

495

Average age 79

Services billed

4,547

239 women, 256 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Atrial fibrillation 47%
Arthritis 46%
Heart failure 38%
Diabetes 31%
Chronic kidney disease 28%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 38 153 $1,019
Infusion, normal saline solution, 250 cc J7050 Office 46 48 $25

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$366 38 —
FARXIGA
$297 22 —
LEQVIO
$212 — —
MULTAQ
$190 12 —
XARELTO
$153 65 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

1,010 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record